I'm of the same understanding that monoclonal antibodies have historically not been able to cross the BBB without some serious trickery.
This article pretty much describes my understanding of the large molecule mAb challenge.
If Leronlimab just "magically" is able to cross the BBB (e.g. piggyback via edndothelial cells)....then WOW. I'm amazed.
However, until the mechanism can be proven and documented....consider me from Missouri - show me.